Managing patients with advanced and metastatic breast cancer: Taxanes and epothilones

Clinical Journal of Oncology Nursing

Volumn 14, Issue 3, 2010, Pages 313-323

  Hurtig, Jane ^a  

^a Tennessee Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST TUMOR; FEMALE; HUMAN; METASTASIS; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 77956206806     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.313-323     Document Type: Article

References (67)

1. Abraxis Bioscience, Inc. (2007). Abraxane® (albumin-bound paclitaxel) [Package insert]. Los Angeles, CA: Author.
2. Albain, K.S., Nag, S.M., Calderillo-Ruiz, G., Jordaan, J.P., Llombart, A.C., Pluzanska, A., O'Shaughnessy, J. (2008). Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Journal of Clinical Oncology, 26, 3950-3957. doi: 10.1200/JCO.2007.11.9362
3. Altmann, K.H. (2005). Recent developments in the chemical biology of epothilones. Current Pharmaceutical Design, 11, 1595-1613.
4. Aventis Pharmaceuticals. (2008). Taxotere® (docetaxel) [Package insert]. Bridgewater, NJ: Author. Retrieved from http://products.sanofi-aventis.us/Taxotere/taxotere.pdf
5. Biganzoli, L., Cufer, T., Bruning, P., Coleman, R., Duchateau, L., Calvert, AH., Piccart, M.J. (2002). Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. Journal of Clinical Oncology, 20, 3114-3121. Retrieved from http://jco.ascopubs.org/cgi/content/full/20/14/3114
6. Bode, C.J., Gupta, M.L., Jr., Reiff, E.A., Suprenant, K.A., Georg, G.I., & Himes, R.H. (2002). Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry, 41, 3870-3874. doi: 10.1021/bi0121611
7. Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Woods, C.M. (1995). Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Research, 55, 2325-2333. Retrieved from http://cancerres.aacrjournals.org/cgi/reprint/55/11/2325
8. Bonneterre, J., Buzdar, A., Nabholtz, J.M., Robertson, J.F., Thurlimann, B., von Euler, M., Steinberg, M. (2001). Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer, 92, 2247-2258. doi: 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
9. Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., van Oosterom, A.T. (1998). Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTCBreast Cancer Cooperative Group. British Journal of Cancer, 77, 2257-2263. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/pdf/brjcancer00088-0203.pdf
10. Bontenbal, M., Creemers, G.J., Braun, H.J., de Boer, A.C., Janssen, J.T., Leys, R.B., Seynaeve, C. (2005). Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. Journal of Clinical Oncology, 23, 7081-7088. doi: 10.1200/JCO.2005.06.236
11. Bristol-Myers Squibb Company. (2007). Taxol® (paclitaxel) [Package insert]. Princeton, NJ: Author. Retrieved from http://packageinserts.bms.com/pi/pi_taxol.pdf
12. Bristol-Myers Squibb Company. (2009). Ixempra® kit (ixabepilone) for injection [Package insert]. Princeton, NJ: Author.
13. Bunnell, C.A., Klimovsky, J., & Thomas, E. (2006). Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline [Abstract 10511]. Proceedings of the American Society of Clinical Oncology, 24. Retrieved from http://jco.ascopubs.org/cgi/mjgca?SEARCHID=1&AUTHOR1=Bunnell&FIRSTINDEX=0&hits=10&RESULTFORMAT=&gca=ascomtg%3B24%2F18_suppl%2F10511
14. Burkhart, C.A., Kavallaris, M., & Band Horwitz, S. (2001). The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochimica et Biophysica Acta, 1471, O1-O9. doi:10.1016/S0304-419X(00)00022-6
15. Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., Zanna, C. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61, 1297-1300.
16. Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M.A. (2003). Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy-Taxane (FACT-taxane). Cancer, 98, 822-831. doi: 10.1002/cncr.11578
17. Chien, A.J., & Moasser, M.M. (2008). Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Seminars in Oncology, 35(2, Suppl. 2), S1-S14. doi: 10.1053/j.seminoncol.2008.02.010
18. Conte, P., Roché, H., Perez, E.A., Sparano, J., Xu, B., Jassem, J., Hortobagyi, G. (2009). Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies [Abstract 6114]. Cancer Research, 69(Suppl.), 393s.
19. Cortes, J., & Baselga, J. (2007). Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist, 12, 271-280. doi: 10.1634/theoncologist.12-3-271
20. Denduluri, N., Low, J.A., Lee, J.J., Berman, A.W., Walshe, J.M., Vatas, U., Swain, S.M. (2007). Phase II trial of ixabepilone, an epothilone Banalog, in patients with metastatic breast cancer previously untreated with taxanes. Journal of Clinical Oncology, 25, 3421-3427. doi: 10.1200/JCO.2006.10.0784
21. Eli Lilly and Company. (2007). Gemzar® (gemcitabine) [Package insert]. Indianapolis, IN: Author.
22. Fojo, T., & Menefee, M. (2007). Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Annals of Oncology, 18(Suppl. 5), v3-v8. doi: 10.1093/annonc/mdm172
23. Gerth, K., Bedorf, N., Hofle, G., Irschik, H., Reichenbach, H. (1996). Epothilones Aand B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. Journal of Antibiotics, 49, 560-563.
24. Giannakakou, P., Gussio, R., Nogales, E., Downing, K.H., Zaharevitz, D., Bollbuck, B., Fojo, T. (2000). Acommon pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 97, 2904-2909. Retrieved from http://www.pnas.org/content/97/6/2904.long
25. Giannakakou, P., Sackett, D.L., Kang, Y.K., Zhan, Z., Buters, J.T., Fojo, T., & Poruchynsky, M.S. (1997). Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. Journal of Biological Chemistry, 272, 17118-17125. Retrieved from http://www.jbc.org/content/272/27/17118.long
26. Goodin, S., Kane, M.P., & Rubin, E.H. (2004). Epothilones: Mechanism of action and biologic activity. Journal of Clinical Oncology, 22, 2015-2025.
27. Gradishar, W.J., Krasnojon, D., Cheporov, S., Makhson, A.N., Manikhas, G.M., & Hawkins, M.J. (2006). Arandomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3w solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC) [Abstract 46]. Breast Cancer Research and Treatment, 100(Suppl. 1), s21.
28. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23, 7794-7803. doi: 10.1200/JCO.2005.04.937
29. Hasegawa, S., Miyoshi, Y., Egawa, C., Ishitobi, M., Taguchi, T., Tamaki, Y., Noguchi, S. (2003). Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNAexpression in human breast cancers. Clinical Cancer Research, 9, 2992-2997. Retrieved from http://clincancerres.aacrjournals.org/content/9/8/2992.long
30. Hortobagyi, G.N., Perez, E.A., Vrdoljak, E., Medina, C., Xu, B., Conte, P., Sparano, J.A. (2008). Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or Calone: Results from two randomized phase III trials [Abstract 186]. Presented at the 2008 ASCO Breast Cancer Symposium, Washington, DC.
31. Jassem, J., Pienkowski, T., Pluzanska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Weil, C. (2001). Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. Journal of Clinical Oncology, 19, 1707-1715. doi: http://jco.ascopubs.org/cgi/content/full/19/6/1707
32. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M.J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249. doi: 10.3322/caac.20006
33. Kamath, K., Wilson, L., Cabral, F., & Jordan, M.A. (2005). BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. Journal of Biological Chemistry, 280, 12902-12907. Retrieved from http://www.jbc.org/content/280/13/12902.long
34. Kar, S., Fan, J., Smith, M.J., Goedert, M., & Amos, L.A. (2003). Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO Journal, 22, 70-77. doi: 10.1093/emboj/cdg001
35. Kavallaris, M., Tait, A.S., Walsh, B.J., He, L., Horwitz, S.B., Norris, M.D., & Haber, M. (2001). Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Research, 61, 5803-5809. Retrieved from http://cancerres.aacrjournals.org/cgi/content/full/61/15/5803
36. Kowalski, R.J., Giannakakou, P., & Hamel, E. (1997). Activities of the microtubule-stabilizing agents epothilones Aand Bwith purified tubulin and in cells resistant to paclitaxel (Taxol®). Journal of Biological Chemistry, 272, 2534-2541. Retrieved from http://www.jbc.org/content/272/4/2534.long
37. Langley, R.E., Carmichael, J., Jones, A.L., Cameron, D.A., Qian, W., Uscinska, B.,Parmar, M. (2005). Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. Journal of Clinical Oncology, 23, 8322-8330. doi: 10.1200/JCO.2005.01.1817
38. Lee, F.Y., Borzilleri, R., Fairchild, C.R., Kim, S.H., Long, B.H., Reventos-Suarez, C., Kramer, R.A. (2001). BMS-247550: Anovel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clinical Cancer Research, 7, 1429-1437. Retrieved from http://clincancerres.aacrjournals.org/content/7/5/1429.long
39. Lee, F.Y., Smykla, R., Johnston, K., Menard, K., McGlinchey, K., Peterson, R.W., Kramer, R. (2009). Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemotherapy and Pharmacology, 63, 201-212. doi: 10.1007/s00280-008-0727-5
40. Low, J.A., Wedam, S.B., Lee, J.J., Berman, A.W., Brufsky, A., Yang, S.X., Swain, S.M. (2005). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone Banalog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 23, 2726-2734. doi: 10.1200/JCO.2005.10.024
41. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., Davidson, N.E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 357, 2666-2676.
42. Nabholtz, J.M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., Pouillart, P. (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21, 968-975. Retrieved from http://jco.ascopubs.org/cgi/content/full/21/6/968
43. Nabholtz, J.M., Senn, H.J., Bezwoda, W.R., Melnychuk, D., Deschenes L., Douma, J., Aapro, M. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. Journal of Clinical Oncology, 17, 1413-1424. Retrieved from http://jco.ascopubs.org/cgi/content/full/17/5/1413
44. National Cancer Institute Cancer Therapy Evaluation Program. (2009). Common terminology criteria for adverse events [v.4.02]. Retrieved from http//ctep.cancer.gov/forms/CTCAEv3.pdf
45. National Comprehensive Cancer Network. (2009). NCCN Practice Guideline in OncologyTM: Breast cancer [v.1.2009]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
46. Nettles, J.H., Li, H., Cornett, B., Krahn, J.M., Snyder, J.P., & Downing, K.H. (2004). The binding mode of epothilone Aon alpha, beta-tubulin by electron crystallography. Science, 305, 866-869. doi: 10.1126/science.1099190
47. Newton, S., Hickey, M., & Marrs, J. (2009). Oncology nursing advisor: A comprehensive guide to clinical practice. St. Louis, MO: Mosby.
48. Perez, E.A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Hortobagyi, G.N. (2007). Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 25, 3407-3414. doi: 10.1200/JCO.2006.09.3849
49. Perez, E.A., Pivot, X., Vrdoljak, E., Sparano, J.A., Vogel, C., Peck, R., Vahdat, L. (2009). Aprospective characterization of the resolution of ixabepilone induced peripheral neuropathy: Data from a large registrational program in patients with metastatic breast cancer [Abstract 6140]. Cancer Research, 69(Suppl.), 401s-402s.
50. Piccart-Gebhart, M.J., Burzykowski, T., Buyse, M., Sledge, G., Carmichael, J., Lück, H.J., Therasse, P. (2008). Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. Journal of Clinical Oncology, 26, 1980-1986. doi: 10.1200/JCO.2007.10.8399
51. Ravdin, P.M., Burris, H.A., III, Cook, G., Eisenberg, P., Kane, M., Bierman, W.A., Bellet, R.E. (1995). Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. Journal of Clinical Oncology, 13, 2879-2885.
52. Ries, L.A.G., Melbert, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J., et al. (Eds.). (2007). SEER cancer statistics review, 1975-2004. Retrieved from http://seer.cancer.gov/csr/1975_2004/
53. Roché, H., Li, R., Ro, J., Vrdoljak, E., Rahman, Z.U., Medina, C., et al. (2009). Ixabepilone plus capecitabine improves progression-free survival in patients with metastatic breast cancer resistant to taxanes: Apooled analysis from two phase III studies [Abstract 2015]. Cancer Research, 69(Suppl), 160s.
54. Roché, H., Yelle, L., Cognetti, F., Mauriac, L., Bunnell, C., Sparano, J., Curé, H. (2007). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone Banalog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of Clinical Oncology, 25, 3415-3420. doi: 10.1200/JCO.2006.09.7535
55. Rugo, H.S., Roché, H., Thomas, E., Blackwell, K., Chung, H.C., Lerzo, G., Perez, E. (2009). Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: Apooled analysis of patients from two large phase III clinical studies [Abstract 3057]. Cancer Research, 69(Suppl.), 225s.
56. Sjöstrom, J., Blomqvist, C., Mouridsen, H., Pluzanska, A., Ottosson-Lönn, S., Bengtsson, N.O., Bergh, J. (1999). Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: Arandomised phase III study with crossover on progression by the Scandanavian Breast Group. European Journal of Cancer, 35, 1194-1201.
57. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783-792.
58. Sledge, G.W., Neuberg, D., Bernardo, P., Ingle, J.N., Martino, S., Rowinsky, E.K., & Wood, W.C. (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). Journal of Clinical Oncology, 21, 588-592. Retrieved from http://jco.ascopubs.org/cgi/content/full/21/4/588
59. Thomas, E., Tabernero, J., Fornier, M., Conte, P., Fumoleau, P., Lluch, A., Martin, M. (2007). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone Banalog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 25, 3399-3406. doi: 10.1200/JCO.2006.08.9102
60. Thomas, E.S., Gomez, H.L., Li, R.K., Chung, H.C., Fein, L.E., Chan, V.F., Roché, H.H. (2007). Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 25, 5210-5217. doi: 10.1200/JCO.2007.12.6557
61. UpToDate. (2010). Paclitaxel nanoparticle albumin bound. Drug information. Dosing: Hepatic impairment" Retrieved from http://www.uptodate.com/online/content/topic.do?topicKey=drug_l_z/53931&selectedTitle=3%7E12&source=search_result#F205677
62. Vahdat, L. (2008). Ixabepilone: Anovel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist, 13, 214-221. doi: 10.1634/theoncologist.2007-0167
63. Vahdat, L., Fein, L.E., Karwal, M.W., Campone, M., Peck, R., Mukhopadhyay, P., & Jassem, J. (2009). Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: Apooled analysis from two phase II studies [Abstract 6117]. Cancer Research, 69(Suppl.), 394s.
64. Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., & Hart, C. (2007). Putting Evidence Into Practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11, 901-913. doi: 10.1188/07.CJON.901-913
65. Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: Areview and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11, 361-376. doi: 10.1188/07.CJON.361-376
66. Wilkes, G., & Barton-Burke, M. (2009). Oncology nursing drug handbook 2009. Sudbury, MA: Jones and Bartlett.
67. Zitella, L.J., Friese, C.R., Hauser, J., Gobel, B.H., Woolery, M., O'Leary, C., & Andrews, F.A. (2006). Putting Evidence Into Practice: Prevention of infection. Clinical Journal of Oncology Nursing, 10, 739-750.